Biochemical engineer, PhD medical science @karolinskainst and @ugent, #ProstateCancer, #LiquidBiopsy & @ProBioTrial researcher. Views are my own
Joined November 2016
- Tweets 343
- Following 642
- Followers 359
- Likes 1,206
31 Photos and videos
Pinned Tweet
20 Aug 2024
Privileged seeing the @ProBioTrial published in @NatureMedicine
My sincerest gratitude for all the dedicated doctors, nurses, lab personnel, trial managers, and most importantly, the patients who made this possible🙏
Thank you @komop_tgkanker for making ProBio possible in🇧🇪
20 Aug 2024
🔥📢 The first results from the @ProBioTrial have been published in @NatureMedicine 🚀🌟
ARPIs outperform taxanes in metastatic #ProstateCancer: an outcome-adaptive randomized platform trial 🌟 nature.com/articles/s41591-0…
[1/10]
4
5
23
1,871
Bram De Laere retweeted
May 20
💡However, comparative randomised evidence is available from the ProBio trial (NCT03903835) in men with ARPI-naïve mCRPC and detectable ctDNA. Compared to taxanes, ARPIs were associated with:
✅ Longer time of clinical benefit (PCWG3)
✅ Longer overall survival
✅ Fewer (S)AE
1
3
4
248
Bram De Laere retweeted
May 20
📣 Pleased to share the publication of the ProBio-mHSPC trial protocol in @EUplatinum Focus: a ctDNA-driven platform trial designed to personalize treatment intensity for patients with metastatic hormone-sensitive prostate cancer.
2
3
6
482
14 Jul 2025
🚨 Our latest study in @ESMO_Open unveils key genomic alterations that could predict treatment response and outcome in #bladdercancer #MIBC patients receiving neoadjuvant chemotherapy (NAC) before cystectomy. 🧬🧪 #precisiononcology
👉sciencedirect.com/science/ar…
1/5
1
2
99
14 Jul 2025
📉 CDKN1A mutations weren’t tied to NAC response but were linked to worse survival outcomes — hinting at prognostic value regardless of molecular subtype. #Biomarkers
4/5
1
58
14 Jul 2025
These findings could refine #PersonalizedMedicine and patient stratification in perioperative MIBC management and inform trials of FGFR inhibitors or alternative therapies. 🔍🎯🧬
👉check out the full study in @ESMO_Open: sciencedirect.com/science/ar…
5/5
1
53
Bram De Laere retweeted
27 May 2025
On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the @ANZUPtrials phase II TheraP study, now published in @NatureMedicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across Australia 🙏🏼 🧵1/10
nature.com/articles/s41591-0…
13
41
103
8,688
But if you ask the companies @Merck to provide drug for a biomarker selection trial like @ProBioTrial, they refuse. Even if you ask for compassionate use for PCa MSI high in the trial!!! @BramDL
1
2
4
409
📢 STORM trial breaking results at #ESTRO25!
🧪 MDT vs ENRT MDT for nodal oligorecurrent PCa.
🧬 ENRT MDT:
✅ Superior bRFS (57% vs 41%, p=0.014)
✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006)
✅ Superior MFS (76% vs 63%, p=0.06)
❌ No increase in ≥G2 GU/GI toxicity
18
104
214
21,704
22 Apr 2025
Proud to share the latest insights from the @ProBioTrial
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant #ProstateCancer
🩸🧬
Full text available on @EurUrolOncol : authors.elsevier.com/sd/arti…
22 Apr 2025
🚨 New Study Alert! 🚨
What if a blood test 🩸 could infer prognosis in advanced prostate cancer? Our latest #ProBio trial study reveals the prognostic power of circulating tumor DNA (ctDNA) 🧬 in #mCRPC
A thread 🧵👇 #CancerResearch #ProstateCancer
[1/8]
1
4
201
Bram De Laere retweeted
22 Apr 2025
🏅Secondary result:
We found a linear relationship between ctDNA 🩸 levels and outcome:
📉 Every 10% increase in ctDNA fraction led to a 9% decrease in the observed survival time.
💡 The more ctDNA in🩸, the worse the outcome!
#PrecisionMedicine
[5/8]
1
4
7
317
Bram De Laere retweeted
22 Apr 2025
🏅Key result:
🧬🩸 Compared to those with detectable ctDNA, men with undetectable ctDNA had
➡️a 60% longer time before treatment stopped working (time to no longer clinically benefiting, NLCB)
➡️a 51% longer overall survival (OS) 📉
#CancerBiomarkers
[4/8]
1
1
2
78
Bram De Laere retweeted
22 Apr 2025
🚨 New Study Alert! 🚨
What if a blood test 🩸 could infer prognosis in advanced prostate cancer? Our latest #ProBio trial study reveals the prognostic power of circulating tumor DNA (ctDNA) 🧬 in #mCRPC
A thread 🧵👇 #CancerResearch #ProstateCancer
[1/8]
2
6
9
651
Bram De Laere retweeted
22 Apr 2025
Important work from the ProBio team! Proud to be a contributor. #probio #prostatecancer
@BramDL @piet_ost @ReneeBultijnck
eur03.safelinks.protection.o…
1
3
93
Bram De Laere retweeted
21 Nov 2024
AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the #ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > bit.ly/3YXuh6j @ProBioTrial
9
14
1,507
6 Nov 2024
A privilege to discuss our 🩸🧬 biomarker-driven @ProBioTrial together with @zklaassen_md
Thank you @urotoday for the invitation 🙏🏻
➡️Visit probiotrial.org or @ProBioTrial for more info!
6 Nov 2024
AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > bit.ly/3YXuh6j
2
10
382
Bram De Laere retweeted
5 Nov 2024
That makes zero sense. And a quote from Edison makes it right. Doing 10.000 trials will induce a ton of financial harm, toxicity and delay the development of other strategies.
'FIRST, DO NO HARM'. Thomas Sydenham.
1
1
127
11 Oct 2024
The very talented Dr @Sj0mpie about to embark on a new journey in his academic career. It has been a privilege to mentor you the past 8 years and advance #ProstateCancer research!
11 Oct 2024
There are a lot of people to thank because a PhD isn't a journey you travel alone.
First, my jury members to critically assess my work (specifically @AdamSharpMedOnc for the great discussion)
1
5
606